VR Logo

Unrated

Nippon India Nifty Pharma ETF


Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Fund -- -0.63 -0.46 2.96 -- -- -- -- -- -- --
S&P BSE Healthcare TRI -- -1.40 -1.30 1.76 -- -- -- -- -- -- --
Equity: Sectoral-Pharma -- -1.16 -0.94 2.10 -- -- -- -- -- -- --
Rank within category -- 2 1 3 -- -- -- -- -- -- --
Number of funds in category 10 13 13 13 12 10 9 6 4 3 3

As on 24-Sep-2021

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
Nippon India Nifty Pharma ETF
Unrated
Jul-21 -- -- -- 0.21 54
Nippon India Pharma Fund
Unrated
Jun-04 42.64 25.03 16.14 1.95 5,667
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund  | Invest Now
Unrated
Jul-18 37.73 26.18 -- 2.00 3,158
SBI Healthcare Opportunities Fund  | Invest Online
Unrated
Jul-99 38.45 22.60 9.57 2.08 2,048
Mirae Asset Healthcare Fund - Regular Plan  | Invest Online
Unrated
Jul-18 42.56 30.25 -- 2.10 1,901

Best & Worst Performance

Best Performance Worst Performance
Return (%) Period Return (%) Period
Week 5.07 26-Aug-2021 - 02-Sep-2021 -4.41 22-Jul-2021 - 29-Jul-2021
Month 4.60 23-Aug-2021 - 22-Sep-2021 -5.87 23-Jul-2021 - 23-Aug-2021
Quarter -- - -- -
Year -- - -- -

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Fund -- -- -- -- -- --
S&P BSE Healthcare TRI* 20.04 21.96 0.73 1.60 -- --
Equity: Sectoral-Pharma* 23.75 19.96 0.99 2.23 0.89 5.48
Rank within category -- -- -- -- -- --
Number of funds in category -- -- -- -- -- --

The Risk Measures have been calculated using calendar month returns for the last three years.

As on

* As on 31-Aug-2021

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 10
Top 10 Stocks (%) 99.47
Top 5 Stocks (%) 76.66
Top 3 Sectors (%) 99.47
Portfolio P/B Ratio 4.76
Portfolio P/E Ratio 30.00

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 91,514 58,801
Giant (%) 23.60 15.06
Large (%) 59.93 45.41
Mid (%) 16.48 32.94
Small (%) -- 8.56
Tiny (%) -- --

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
up Sun Pharmaceutical Industries Healthcare 30.76 23.47 22.79 23.47
up Divi's Laboratories Healthcare 66.09 18.06 17.06 18.06
up Dr. Reddy's Lab Healthcare 45.90 15.64 15.61 15.64
up Cipla Healthcare 30.69 13.18 12.75 13.18
up Lupin Healthcare 25.45 7.27 6.31 6.31
up Aurobindo Pharma Healthcare 7.95 7.03 5.60 5.60
up Alkem Laboratories Healthcare 29.33 4.69 4.17 4.69
up Biocon Healthcare 64.02 4.80 4.48 4.48
up Torrent Pharmaceuticals Healthcare 41.60 4.16 4.10 4.16
up Cadila Healthcare Healthcare 25.51 4.09 3.88 3.88

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 31-Aug-2021

Fund Manager

— Mehul Dama since 21-Jun-2021

Education: Mr. Dama has done C.A. & B.Com

Experience: Prior to joining Nippon India Mutual Fund, he has worked with Goldman Sachs Asset Management(India) Private Ltd. as Vice President, Benchmark Asset Management Company Private Ltd. as Assistant Vice President and Lovelock & Lewes as Assistant Manager.

Funds Managed:


-0.63%

Change from previous, NAV as on 24-Sep-2021

Growth: ₹ 14.3400


Investment Strategy

The scheme seeks to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors.

Investment Details

Minimum Investment (₹) 1,000
Minimum Addl Investment (₹) --
Minimum SIP Investment (₹) --
Minimum No of Cheques --
Minimum Withdrawal (₹) --
Minimum Balance (₹) --
Lock-in Period Not Applicable
Exit Load 0

Basic Details

Fund House: Nippon India Mutual Fund
Launch Date: 02-Jul-2021
Return Since Launch: 43.40%
Benchmark: NIFTY Pharma TRI
Riskometer: Very High
Type: Open-ended
Assets: ₹ 54 Cr (As on 31-Aug-2021)
Expense: 0.21% (As on 31-Aug-2021)
Risk Grade: --
Return Grade: --
Turnover: --

Contact Information

AMC: Nippon India Life Asset Management Ltd.

Address: Reliance Centre, 7th Floor, South Wing Off Western Express Highway Santacruz (East) Mumbai - 400055

Phone: 022-68334800 / 18602660111

Fax: 022-33037662

Email: [email protected]

Website: http://www.nipponindiamf.com

Registrar & Transfer Agent: KFin Technologies Pvt Ltd.

Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016

Phone: 040-44857874

Email: [email protected]

Website: www.karvymfs.com

Upcoming Video

Viewpoint

The Case for ESG Investing

DateThursday, 30-Sep-2021
Time04:00 PM - 04:30 PM